Qiagen Shares - Goldman Sachs disclosure lifts attention
Published on 06/18/2026 at 13:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edited by ad hoc news Thursday Desk. Verified prior to publication on 06/18/2026, 13:05 UTC. Details in the imprint.
Qiagen (NL0012169213) is the focus after a Dutch disclosure tied to Goldman Sachs, which Reuters-linked market coverage and TipRanks both attribute to an AFM filing. The move in attention is tied to a substantial voting-interest notice, not to a company guidance update.Reuters-linked market report on the AFM notice
All news and analysis on Qiagen stock
Use this hub for coverage, price data, and company updates tied to Qiagen shares.
What Reuters-linked coverage says
TipRanks says Qiagen reported that the Dutch regulator AFM was notified about a substantial shareholding disclosure connected to Goldman Sachs Group.TipRanks summary of the disclosure
The same market item points to a 3.03% voting interest. That makes the filing relevant for investors tracking ownership changes around the stock.
Thursday chart check
Thursday’s focus is the chart. MarketBeat shows Qiagen shares closed at $36.66 on 06/17/2026, down 1.52% on the day, with a consensus price target of $44.98.
The same page lists extended trading at $36.25. It also places Qiagen in the medical sector and the biomedical/gene products industry.MarketBeat quote and consensus page
What Qiagen sells
Qiagen develops sample preparation and molecular testing products for life sciences, molecular diagnostics, and applied testing. Its portfolio includes instruments, consumables, and assay workflows used in laboratories.
Where the stock trades today
The shares of Qiagen (NL0012169213) trade on the NYSE as QGEN at $36.66 as of 06/17/2026, 03:59 PM Eastern.
Qiagen at a glance
- Company: Qiagen N.V.
- ISIN: NL0012169213
- Ticker: QGEN
- Venue: NYSE
- Price (as of 06/17/2026, 03:59 PM Eastern): $36.66
- Market cap: $7.54 billion USD (as of 06/2026)
- Sector / Industry: Medical - Biomed/Gene Products
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
